# OnCo record lunresertib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lunresertib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lunresertib" ;
  schema:name "Lunresertib"@en ;
  schema:alternateName "RP-6306"@en ;
  schema:description "Lunresertib is an experimental oral small molecule kinase inhibitor from Repare Therapeutics, in phase 2 trials for advanced solid tumours, ER-positive HER2-negative breast cancer resistant to CDK4/6 inhibitors and TP53-mutant ovarian and uterine cancer."@en ;
  schema:url <https://onco.cc/drugs/lunresertib/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1808158/000119312525159942/d944012dex991.htm>, <https://www.sec.gov/Archives/edgar/data/1808158/000119312525159942/d944012dex991.htm>, <https://clinicaltrials.gov/api/v2/studies/NCT04855656>, <https://clinicaltrials.gov/search?intr=RP-6306> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral small molecule kinase inhibitor" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/breast-cancer/> ;
  onco:companies <https://onco.cc/companies/repare-therapeutics/>, <https://onco.cc/companies/debiopharm/> ;
  onco:trials <https://onco.cc/trials/nct04855656/>, <https://onco.cc/trials/nct05601440/>, <https://onco.cc/trials/nct05605509/>, <https://onco.cc/trials/nct05147350/>, <https://onco.cc/trials/nct05147272/>, <https://onco.cc/trials/nct06107868/> .